Get 50% OFF This Monsoon!

Advertisement
AdvertisementAdvertisement
logo

Cohance Lifesciences

COHANCE
Mid Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement
AdvertisementAdvertisement

Cohance Lifesciences Share price and Fundamental Analysis

View All Details
View All Details
Suven Pharmaceuticals Limited (SPL) is a bio-pharmaceutical company, incorporated on 6th November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
Company Incorporation2018
ChairmanJ V Ramudu
Head QuartersNA
Previous NameSuven Pharmaceuticals Ltd

Key Metrics

Market Cap (Cr)
38,029
PE Ratio
142.01
Industry P/E
34.33
PEG Ratio
-3.49
ROE
15.79%
ROCE
14.06%
ROA
8.73%
Total Debt (Cr)
98.64
Debt to Equity
0.16
Dividend Yield
0%
EPS
7
Book Value & P/B
60.86 x 16.33
Face Value
1
Outstanding Shares(Cr)
38.26
Current Ratio
3.26
EV to Sales
31.91

Included In

+More

Stock Returns

1 Week-3.94%
1 Month-7.68%
6 Months-22.06%
1 Year+31.81%
3 Years+115.49%
5 Years+277.78%

CAGR

1 Year CAGR

Revenue Growth

-21.56%

Net Profit Growth

-26.99%

Operating Profit Growth

-23.69%

Dividend Growth

-100%

Stock Returns CAGR

+34.85%
no_data

No Stocks

Smart Score

2.1
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

/ View Standalone
PARTICULARS

Total Revenue

Total Expenses

Operating Expense

Operating Profit

Interest

Depreciation & Amortization

Profit Before Tax

Tax

Profit after tax

Adj EPS in Rs - Basic

Adj EPS in Rs - Diluted

Profit and Loss Statement

/ View Standalone
Credit Rating
Director Report
Chairman Report
Auditor Report

Balance sheet

/ View Standalone

Cashflow Statement

/ View Standalone
May 25

Promoters : 66.41%

FIIs : 7.38%

DIIs : 11.02%

Public : 15.19%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in May 2025 Qtr
Promoter Shareholding Increased by 16.31% to 66.41% in May 2025 Qtr
FII Shareholding Decreased by 3.67% to 7.38% in May 2025 Qtr
DII Shareholding Decreased by 5.59% to 11.02% in May 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Cohance Lifesciences Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Cohance Lifesciences Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Suven Pharmaceuticals Limited (SPL) is a bio-pharmaceutical company, incorporated on 6th November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

The Company is a CDMO that supports global life sciences industry and fine chemical majors in their NCE development endeavors. Its services include custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs and formulations. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.

During the year 2019-20, Suven Life Sciences Ltd. (SLSL) has transferred the CRAMS business undertaking to the Company in accordance with the Scheme of Arrangement (Demerger) approved by the Hon'ble NCLT, Hyderabad Bench now integrated with Contract Development and Manufacturing Operations (CDMO) business model of the Company.

In terms of the sanctioned Scheme, the Company issued and allotted 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each of SPL for every 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each held by each shareholder in the Demerged Company (SLSL) as on the Record Date (i.e., 22nd January, 2020), thereby resulted in a mirror shareholding of SLSL in the Company. The equity shares of the Company were listed to trade w.e.f. 09th March, 2020.

The Board of Directors in its meeting held on August 17, 2020 considered, approved and recommended an issue of bonus shares in the proportion of (1:1) one new equity share of the Company of Re 1 each for every one existing equity share of the Company of Re 1 each.

The company has a massive Rs 320-crore capex plan. Suven has invested Rs 120 crore in 2019-20. The balance is to be invested in 2020-21.

During the year 2019-20, the Company invested USD35 million in Rising Pharma Holdings, Inc., USA through its wholly owned subsidiary, Suven Pharma, Inc., USA. Suven Pharma, Inc., in USA was originally formed by Suven Life Sciences Ltd while pursuing various business opportunities in CRAMS business undertaking during the demerger transition period now integrated with CDMO business of the Company, as per the decisions taken by the Board of the Company and of the Demerged Company i.e., Suven Life Sciences Ltd, in accordance with the enabling provisions of Scheme of Arrangement as sanctioned by Hon'ble NCLT Hyderabad Bench. As a result, Suven Pharma, Inc., in USA has become wholly owned subsidiary of the company during the FY 2019-2020.

As on 31 March 2020,the company has one subsidiary and one associate company under its roof.

The company filed 11 ANDAs as on March 31, 2020 and three of those secured the green light from the regulator.

The Board has allotted the Bonus shares at 1:1 ratio in its Board Meeting held on 29 September 2020. Accordingly the number of shares increased from 12,72,82,478 to 25,45,64,956..

In 2022, the Company filed 17 ANDAs of which 9 had received approvals and 8 products were launched up to March, 2022.

During year 2022, Company acquired 100% stake in Casper Pharma Private Limited, a Hyderabad based SEZ unit and Casper Pharma became a Wholly Owned Subsidiary of the company.

Cohance Lifesciences Share Price

Cohance Lifesciences share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Cohance Lifesciences Market Cap

Market capitalization of Cohance Lifesciences indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Cohance Lifesciences is valued compared to its competitors.

Cohance Lifesciences PE Ratio

Cohance Lifesciences PE ratio helps investors understand what is the market value of each stock compared to Cohance Lifesciences 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Cohance Lifesciences PEG Ratio

The PEG ratio of Cohance Lifesciences evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Cohance Lifesciences ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Cohance Lifesciences generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Cohance Lifesciences ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Cohance Lifesciences in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Cohance Lifesciences Total Debt

Total debt of Cohance Lifesciences shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Cohance Lifesciences Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Cohance Lifesciences compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Cohance Lifesciences CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Cohance Lifesciences over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Cohance Lifesciences Technical Analysis

Technical analysis of Cohance Lifesciences helps investors get an insight into when they can enter or exit the stock. Key components of Cohance Lifesciences Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Cohance Lifesciences shares often struggle to rise above due to selling pressure.

Cohance Lifesciences Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Cohance Lifesciences ’s financial health and profitability.

Cohance Lifesciences Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Cohance Lifesciences Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Cohance Lifesciences Financials

The financials of Cohance Lifesciences provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Cohance Lifesciences Profit and Loss Statements

The profit and loss statement of Cohance Lifesciences highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Cohance Lifesciences .

Cohance Lifesciences Balance Sheet

The balance sheet presents a snapshot of Cohance Lifesciences ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Cohance Lifesciences Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App

Download the App